Clinical trial
Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant…
NCT00110851 · Wellstat Therapeutics, Industry · Completed
Key facts
| NCT number | NCT00110851 |
|---|---|
| Title | Safety and Efficacy Study of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) |
| Official title | A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Effects of PN2034 in Type 2 Diabetes Patients on Concomitant Rosiglitazone and Metformin (or Avandamet) Therapy |
| Lead sponsor | Wellstat Therapeutics, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | rosiglitazone, metformin, PN2034 |
| Enrollment | 90 |
| Start date | Apr 1, 2005 |
| Completion | Aug 1, 2007 |
| First posted | May 16, 2005 |
| Last update posted | Aug 23, 2007 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: